{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:23:53Z","timestamp":1770978233649,"version":"3.50.1"},"reference-count":0,"publisher":"Touch Medical Media, Ltd.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:p>Diabetic macular oedema (DMO) is a leading cause of vision loss in the working-age population worldwide. Corticosteroid drugs have been demonstrated to inhibit the expression of both the vascular endothelial growth factor (VEGF) gene and other anti-inflammatory mediators, such as prostaglandins. Triamcinolone, fluocinolone and dexamethasone are the main steroids that have been studied for the treatment of macular oedema. Over the last few years, several studies have suggested an important role for dexamethasone in the management of DMO. The dexamethasone intravitreal implant (DEX implant) (Ozurdex\u00ae; Allergan, Inc., Irvine, CA) is a novel approach approved by the US Food and Drug Administration (FDA) and by the EU for the intravitreal treatment of macular oedema after branch or central retinal vein occlusion, and for the treatment of non-infectious uveitis affecting the posterior segment of the eye. We reviewed manuscripts that had investigated the pharmacokinetics, efficacy and safety of the DEX implant regarding DMO treatment.<\/jats:p>","DOI":"10.17925\/ee.2014.10.02.111","type":"journal-article","created":{"date-parts":[[2015,6,20]],"date-time":"2015-06-20T05:59:30Z","timestamp":1434779970000},"page":"111","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema"],"prefix":"10.17925","volume":"10","author":[{"given":"Marco Dutra","family":"Medeiros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micol","family":"Alkabes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Nucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Consultant Ophthalmologist \u2013 Vitreoretinal Surgeon, Central Lisbon Hospital Center, NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Consultant Ophthalmologist \u2013 Vitreoretinal Surgeon, University Eye Clinic, San Giuseppe Hospital, University of Milan, Milan, Italy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Professor of Ophthalmology, University Eye Clinic, San Giuseppe Hospital, University of Milan, Milan, Italy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7274","container-title":["European Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchendocrinology.com\/diabetes\/journal-articles\/effectiveness-of-the-dexamethasone-intravitreal-implant-for-treatment-of-patients-with-diabetic-macular-oedema\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:00:45Z","timestamp":1764745245000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.touchendocrinology.com\/articles\/effectiveness-dexamethasone-intravitreal-implant-treatment-patients-diabetic-macular-oedema"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"alternative-id":["EE.2014.10.02.111"],"URL":"https:\/\/doi.org\/10.17925\/ee.2014.10.02.111","relation":{},"ISSN":["1758-3772"],"issn-type":[{"value":"1758-3772","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}